Life Sciences Reaches New Heights at Sydney Sky Tower on October 21, 2013
Interested investors can view the presentations via Live Webcast while the companies present over dinner to high net worth investors, institutions and broking organisations.
New Zealand based Life Sciences company, Living Cell Technologies (ASX:LCT) (OTCMKTS:LVCLY) with Managing Director Andrea Grant is just one of the companies, presenting their cell encapsulation and implantation for human therapeutics technologies. Dr Grant has over 15 years executive experience in pharmaceutical and biotech companies in Europe, USA and New Zealand. She has both a BA Hons in Biochemistry and a PhD in Neuroscience from Cambridge University in the UK. Following her PhD she joined the R&D division of GlaxoSmithKline (UK) where her she was responsible for research and development of novel drug targets for treatment of neurological disorders including Alzheimer's, epilepsy and Parkinson's.
To view the Live Webcast at 6:00PM AESTD on October 21, simply visit:
or register to attend the presentation by applying at:
(Attending the event is limited to capital markets professionals.)
Investors seeking opportunities in the Biotech and Life Sciences sectors are invited to register for daily updates from:
Investorium.tv is a Video Streaming and Live Financial Industry Event featuring CEOs of Public Companies held at Premier Venues in New York, Vancouver and Sydney. Investorium.tv records and video streams the events on "state of the art" digital recording and webcasting equipment, making high definition broadcast quality productions available to Members and the professional investment community.
About Living Cell Technologies Limited
Living Cell Technologies Limited (ASX:LCT) (OTCMKTS:LVCLY) is a New Zealand biotechnology company focused on discovering, developing and commercialising regenerative cell treatments which restore function using naturally occurring cells.
LCT’s lead product NTCELL(R) is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing neurotrophic factors to prevent and repair disease induced nerve degeneration.
The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and showed encouraging clinical efficacy. A Phase IIb trial has been designed to further evaluate NTCELLs potential as a disease-modifying treatment for patients with Parkinson’s disease.
NTCELL has the potential to be used in a number of other central nervous system degenerative diseases such as Huntington’s, Alzheimer’s and motor neurone diseases.
Living Cell Technologies Limited